Paradigm Changes in Diabetes Management Guidelines: American Diabetes Association 2018.
- Author:
Jeong Hyun PARK
1
Author Information
- Publication Type:Editorial
- Keywords: Agonist; Cardiovascular diseases; Diabetes mellitus; Glucagon-like peptide-1 receptor; Inhibitor; Mortality; Sodium-glucose transporter 2
- MeSH: Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Life Style; Metformin; Mortality; Sodium-Glucose Transporter 2
- From:Journal of Korean Diabetes 2018;19(2):71-75
- CountryRepublic of Korea
- Language:Korean
- Abstract: The management of type 2 diabetes mellitus should comprise healthy lifestyle modifications along with tailored pharmacologic treatment. Traditionally, the American Diabetes Association (ADA)'s Diabetes Management Guidelines have not prioritized specific anti-diabetic drugs over others with regard to cardiovascular disease (CVD) and mortality prevention. Recently, two novel anti-diabetic medications proved to be significantly protective against future CVD and mortality, regardless of the glycemic levels achieved in type 2 diabetic patients with pre-existing CVD. The 2018 ADA Guidelines recommend SGLT2 inhibitor and/or GLP-1 receptor agonist be used for type 2 diabetes patients with atherosclerotic CVD after metformin monotherapy failure. Considering the value of CVD protection in the management of diabetes mellitus, this minor guideline adjustment could have far-reaching implications.
